@article{APS10795,
author = {Jie Li and Yan Zhou and Guy Eelen and Qing-tong Zhou and Wen-bo Feng and Viktorija Labroska and Fen-fen Ma and Hui-ping Lu and Mieke Dewerchin and Peter Carmeliet and Ming-wei Wang and De-hua Yang},
title = {A high-throughput screening campaign against PFKFB3 identified potential inhibitors with novel scaffolds},
journal = {Acta Pharmacologica Sinica},
volume = {44},
number = {3},
year = {2023},
keywords = {},
abstract = {The growth of solid tumors depends on tumor vascularization and the endothelial cells (ECs) that line the lumen of blood vessels. ECs generate a large fraction of ATP through glycolysis, and elevation of their glycolytic activity is associated with angiogenic behavior in solid tumors. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) positively regulates glycolysis via fructose-2/6-bisphosphate, the product of its kinase activity. Partial inhibition of glycolysis in tumor ECs by targeting PFKFB3 normalizes the otherwise abnormal tumor vessels, thereby reducing metastasis and improving the outcome of chemotherapy. Although a limited number of tool compounds exist, orally available PFKFB3 inhibitors are unavailable. In this study we conducted a high-throughput screening campaign against the kinase activity of PFKFB3, involving 250,240 chemical compounds. A total of 507 initial hits showing >50% inhibition at 20 μM were identified, 66 of them plus 1 analog from a similarity search consistently displayed low IC50 values (<10 μM). In vitro experiments yielded 22 nontoxic hits that suppressed the tube formation of primary human umbilical vein ECs at 10 μM. Of them, 15 exhibited binding affinity to PFKFB3 in surface plasmon resonance assays, including 3 (WNN0403-E003, WNN1352-H007 and WNN1542-F004) that passed the pan-assay interference compounds screening without warning flags. This study provides potential leads to the development of new PFKFB3 inhibitors.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10795}
}